Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 11/20 | 0.98 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.98 |
| ▸ | DHFR known ✓ | P00374 | 4/20 | 0.98 |
| ▸ | FOLR1 | P15328 | 7/20 | 0.98 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 0.98 |
| ▸ | SLC19A1 | P41440 | 6/20 | 0.98 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.98 |
| ▸ | ATIC | P31939 | 2/20 | 0.98 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.98 |
| ▸ | FRK | P42685 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL14321276 | 1.00 | GART (0.98) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL209720 | 0.99 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL7144918 | 0.99 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL5959741 | 0.99 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL24846066 | 0.96 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967367 | 0.96 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL15078815 | 0.96 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967346 | 0.96 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967345 | 0.96 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL29710616 | 0.96 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138521-B2 | Crystalline of N-[4-[2-(2-Amino-4,7-dihydro-4oxo-3H-pyrrolo[2,3-D]pyrimidin-5-YL)ethyl]benzoyl]-L-glutamic acid and process therefor | ELI LILLY AND COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| US-20030216416-A1 | Novel crystalline of n-[4-[2-(2-amino-4,7-dihydro-4oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor | ELI LILLY AND COMPANY | 2003-11-20 | — | — | US | claimed |
| JP-2003530321-A | — | — | 2003-10-14 | — | — | JP | claimed |
| EP-1259513-B1 | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | LILLY CO ELI (US) | 2003-09-10 | — | — | EP | claimed |
| EP-1259513-A2 | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1212325-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001062760-A2 | A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | ELI LILLY AND COMPANY (US) | 2001-08-30 | — | — | WO | claimed |
| WO-2001014379-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2001-03-01 | — | — | WO | claimed |
| CN-112442038-B | Industrial preparation method of pemetrexed disodium | 德州德药制药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112174970-B | Method for preparing pemetrexed disodium with high yield | 德州德药制药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-112442038-A | Industrial preparation method of pemetrexed disodium | 德州德药制药有限公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-112174970-A | Method for preparing pemetrexed disodium in high yield | 德州德药制药有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-9174991-B2 | Crystalline form of pemetrexed disodium | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | UNIVERSITY OF ZURICH (CH) | 2012-12-27 | — | — | US | disclosed |
| EP-1212325-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1212325-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014379-A3 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | LILLY CO ELI (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001062760-A2 | A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | ELI LILLY AND COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001014379-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001014379-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | TYMP, TYMS, MTHFD1 | GART 149/4885TYMS 2/4885DHFR 11/4885 |
| US-20030216416-A1 | Novel crystalline of n-[4-[2-(2-amino-4,7-dihydro-4oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor | SLC7A11, SLC7A1, DHFR | GART 71/4885TYMS 119/4885DHFR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.